First human tests begin for experimental lung injury treatment
NCT ID NCT07449572
Summary
This early-stage study is testing the safety of a new antibody drug called HT31-1 in healthy volunteers. The drug is being developed to treat Acute Respiratory Distress Syndrome (ARDS), a serious lung condition often caused by infections. Researchers will give increasing doses to 24 healthy adults to check for side effects and determine safe levels for future studies in ARDS patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University (VCU Health)
Richmond, Virginia, 23298, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.